Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Xaira Therapeutics
AddedJun 24, 2026
UpdatedJul 7, 2026
Xaira Therapeutics

Xaira Therapeutics

Series A

Xaira Therapeutics is an integrated biotechnology company pioneering AI for drug discovery and development of life-changing medicines.

HQ
South San Francisco, CA, US
Founded
2023
Overview
Compare
Fundraising
Employees
Website

Xaira Therapeutics emerged in 2024 with a record $1B Series A to harness artificial intelligence for reimagining drug discovery. Headquartered in South San Francisco, the company combines machine learning, data generation and therapeutic product development.

It was co-founded by David Baker and is led by Chairman and CEO Marc Tessier-Lavigne. The platform builds predictive AI models across the drug discovery process.

Xaira Therapeutics - Similar Companies

X-37 logo

X-37

x37.ai

Aria Pharmaceuticals logo

Aria Pharmaceuticals

Terray Therapeutics logo

Terray Therapeutics

terraytx.com

X4 Pharmaceuticals logo

X4 Pharmaceuticals

x4pharma.com

XRad Therapeutics logo

XRad Therapeutics

XtalPi logo

XtalPi

xtalpi.com

Empress Therapeutics logo

Empress Therapeutics

empresstx.com

Aether Therapeutics logo

Aether Therapeutics

Aureka Biotechnologies logo

Aureka Biotechnologies

aurekabio.com

BioXcel Therapeutics logo

BioXcel Therapeutics

Airna logo

Airna

airna.com

NeuroX1 logo

NeuroX1

neurox1.com

Iambic Therapeutics logo

Iambic Therapeutics

iambic.ai

Aristea Therapeutics logo

Aristea Therapeutics

Kimia Therapeutics logo

Kimia Therapeutics

kimiatx.com

Xaira Therapeutics - Quick Facts

Who are Xaira Therapeutics' competitors?

Companies similar to Xaira Therapeutics include X-37, Aria Pharmaceuticals, Terray Therapeutics and X4 Pharmaceuticals.

When was Xaira Therapeutics founded?

Xaira Therapeutics was founded in 2023.

Where is Xaira Therapeutics' headquarters located?

Xaira Therapeutics' headquarters is located in South San Francisco, CA, US.

When was Xaira Therapeutics' last funding round?

Xaira Therapeutics' most recent funding round was for $1B (USD) in April 2024.

How much has Xaira Therapeutics raised to-date?

As of Apr 23, 2024, Xaira Therapeutics has raised a total of $1B (USD).

Xaira Therapeutics - Classification

Industry
  • Drug Discovery